HaemaLogiX is highlighted in Drug Target Review for work identifying KMA and LMA antigens as promising therapeutic targets in plasma cell dyscrasias, a group of disorders that includes multiple myeloma. The piece outlines why these antigens are considered high‑value: they show selective expression on malignant plasma cells and present opportunities for targeted modalities such as antibody–drug conjugates and engineered cell therapies.

Targeting KMA and LMA could improve tumour specificity and reduce off‑target toxicity compared with broader approaches, potentially enabling deeper remissions for patients with relapsed or refractory disease. The article highlights our client’s role in advancing antigen validation and preclinical development, including biomarker characterisation and early translational studies that support clinical candidate selection.

Read the full story here.